Literature DB >> 12674328

Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast.

Anandarup Gupta1, Beth S Lee, Mohammed A Khadeer, Zhihui Tang, Meenakshi Chellaiah, Yousef Abu-Amer, Joshua Goldknopf, Keith A Hruska.   

Abstract

Leupaxin is a cytoskeleton adaptor protein that was first identified in human macrophages and was found to share homology with the focal adhesion protein, paxillin. Leupaxin possesses several protein-binding domains that have been implicated in targeting proteins such as focal adhesion kinase (pp125FAK) to focal adhesions. Leupaxin can be detected in monocytes and osteoclasts, both cells of hematopoietic origin. We have identified leupaxin to be a component of the osteoclast podosomal signaling complex. We have found that leupaxin in murine osteoclasts is associated with both PYK2 and pp125FAK in the osteoclast. Treatment of osteoclasts with TNF-alpha and soluble osteopontin were found to stimulate tyrosine phosphorylation of both leupaxin and leupaxin-associated PYK2. Leupaxin was found to co-immunoprecipitate with the protein tyrosine phosphatase PTP-PEST. The cellular distribution of leupaxin, PYK2, and protein tyrosine phosphorylation-PEST co-localized at or near the osteoclast podosomal complex. Leupaxin was also found to associate with the ARF-GTPase-activating protein, paxillin kinase linker p95PKL, thereby providing a link to regulators of cytoskeletal dynamics in the osteoclast. Overexpression of leupaxin by transduction into osteoclasts evoked numerous cytoplasmic projections at the leading edge of the cell, resembling a motile phenotype. Finally, in vitro inhibition of leupaxin expression in the osteoclast led to a decrease in resorptive capacity. Our data suggest that leupaxin may be a critical nucleating component of the osteoclast podosomal signaling complex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12674328     DOI: 10.1359/jbmr.2003.18.4.669

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

1.  Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts.

Authors:  Tao Ma; Kavitha Sadashivaiah; Nandakumar Madayiputhiya; Meenakshi A Chellaiah
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

2.  A small molecule that inhibits the interaction of paxillin and alpha 4 integrin inhibits accumulation of mononuclear leukocytes at a site of inflammation.

Authors:  Christiane Kummer; Brian G Petrich; David M Rose; Mark H Ginsberg
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

3.  Autoimmune manifestations in aged mice arise from early-life immune dysregulation.

Authors:  Tamer I Mahmoud; Jingya Wang; Jodi L Karnell; Qiming Wang; Shu Wang; Brian Naiman; Phillip Gross; Philip Z Brohawn; Chris Morehouse; Jordan Aoyama; Clive Wasserfall; Laura Carter; Mark A Atkinson; David V Serreze; Helen Braley-Mullen; Tomas Mustelin; Roland Kolbeck; Ronald Herbst; Rachel Ettinger
Journal:  Sci Transl Med       Date:  2016-10-19       Impact factor: 17.956

4.  Leupaxin is similar to paxillin in focal adhesion targeting and tyrosine phosphorylation but has distinct roles in cell adhesion and spreading.

Authors:  Pei-Wen Chen; Glenn S Kroog
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

5.  Diverse roles for the paxillin family of proteins in cancer.

Authors:  Nicholas O Deakin; Jeanine Pignatelli; Christopher E Turner
Journal:  Genes Cancer       Date:  2012-05

6.  Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.

Authors:  Silke Kaulfuss; Michal Grzmil; Bernhard Hemmerlein; Paul Thelen; Stefan Schweyer; Jürgen Neesen; Lukas Bubendorf; Andrew G Glass; Hubertus Jarry; Bernd Auber; Peter Burfeind
Journal:  Mol Endocrinol       Date:  2008-05-01

7.  Regulation of β-catenin transcription activity by leupaxin in hepatocellular carcinoma.

Authors:  Jia Shi; Wen-Jie Wu; Gang Hu; Xin Yu; Ge-Shu Yu; Han Lu; Ming-Liang Yang; Bin Liu; Zhi-Xiang Wu
Journal:  Tumour Biol       Date:  2015-09-11

8.  Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

Authors:  Ramasamy Jagadeeswaran; Hanna Surawska; Soundararajan Krishnaswamy; Varalakshmi Janamanchi; A Craig Mackinnon; Tanguy Y Seiwert; Sivakumar Loganathan; Rajani Kanteti; Trevor Reichman; Vidya Nallasura; Stuart Schwartz; Leonardo Faoro; Yi-Ching Wang; Luc Girard; Maria S Tretiakova; Salman Ahmed; Osvaldo Zumba; Lioubov Soulii; Vytas P Bindokas; Livia L Szeto; Gavin J Gordon; Raphael Bueno; David Sugarbaker; Mark W Lingen; Martin Sattler; Thomas Krausz; Wickii Vigneswaran; Viswanathan Natarajan; John Minna; Everett E Vokes; Mark K Ferguson; Aliya N Husain; Ravi Salgia
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

9.  GIT1 utilizes a focal adhesion targeting-homology domain to bind paxillin.

Authors:  Robert Schmalzigaug; Marie-Line Garron; J Tyler Roseman; Yanghui Xing; Collin E Davidson; Stefan T Arold; Richard T Premont
Journal:  Cell Signal       Date:  2007-03-30       Impact factor: 4.315

10.  The LIM protein leupaxin is enriched in smooth muscle and functions as an serum response factor cofactor to induce smooth muscle cell gene transcription.

Authors:  Liisa J Sundberg-Smith; Laura A DiMichele; Rebecca L Sayers; Christopher P Mack; Joan M Taylor
Journal:  Circ Res       Date:  2008-05-22       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.